While one study found lower rates of preterm birth alongside higher rates of hypertensive disorders, another found fewer ...

Use of GLP-1 receptor agonists to treat type 2 diabetes is not associated with an increased risk of suicidality compared with ...

Companies such as PepsiCo and Mondelēz haven’t seen an impact on business, while Healthy Choice maker Conagra sees the ...

Biocon announced the launch of its GLP-1 peptide, Liraglutide, for diabetes and obesity, in the United Kingdom (U.K.). The drug-device combination will be marketed in the U.K. under the brand names ...

Companies such as PepsiCo and Mondelēz haven’t seen an impact on business, while Healthy Choice maker Conagra sees the ...

Outsourcing Facilities Association and North American Custom Laboratories allege the FDA removed semaglutide from its ...

There are additional considerations that physicians need to consider when prescribing GLP-1s to patients with disabilities or ...

Lexaria executing a triple-pronged strategy in obesity and diabetes Semaglutide recently approved to treat chronic kidney disease KELOWNA, BC / ACCESS Newswire / February 27, 2025 / Lexaria Bioscience ...

Lexaria executing a triple-pronged strategy in obesity and diabetesSemaglutide recently approved to treat chronic kidney disease KELOWNA, BC / ACCESS Newswire / February 27, 2025 / Lexaria Bioscience ...

Risk of suicidality wasn't higher for type 2 diabetes patients starting on GLP-1 receptor agonists than for those on two other popular classes of diabetes drugs, a U.K. cohort study found. In fully ...

Last week, the US Food and Drug Administration (FDA) announced the end of a years-long shortage of semaglutide injection products — a ...